Lodine (etodolac)
Company: Wyeth-Ayerst Laboratories
Approval Status: Approved July 1996
Treatment for: rheumatoid arthritis
Areas: Endocrinology; Rheumatology
Possible similar drugs: Lodine XL; Lodine XL
| General Information | Clinical Results | Literature References |
General Information
Lodine has been approved for the treatment of rheumatoid arthritis. Lodine is a nonsteroidal anti-inflammatory drug (NSAID).
At the same time the FDA has cleared for market a new 500 mg dosage strength.
Clinical Results
The safety and efficacy of Lodine in relieving the signs and symptoms of rheumatoid arthritis were established in a three-year, double-blind, multicenter clinical trial involving 1,446 subjects with active rheumatoid arthritis. Data from the study indicated that doses of Lodine at 1,000 mg/day were efficacious and well tolerated in subjects being treated for active rheumatoid arthritis.
Literature References
Lanza F, Rack MF, Lynn M et al. "An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa." J Rheumatology 1987; 14:338-341.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
